Pneumolysin as a potential therapeutic target in severe pneumococcal disease

Isturiz, 2010, Clinical and economic burden of pneumonia among adults in Latin America, Int J Infect Dis, 14, e852, 10.1016/j.ijid.2010.02.2262 File, 2010, Burden of community-acquired pneumonia in North American adults, Postgrad Med, 122, 130, 10.3810/pgm.2010.03.2130 Song, 2011, Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region, Int J Antimicrob Agents, 38, 108 Welte, 2012, Clinical and economic burden of community-acquired pneumonia among adults in Europe, Thorax, 67, 71, 10.1136/thx.2009.129502 Sanz Herrero, 2012, Microbiology and risk factors for community-acquired pneumonia, Semin Respir Crit Care Med, 33, 220, 10.1055/s-0032-1315634 Drijkoningen, 2014, Pneumococcal infection in adults: burden of disease, Clin Microbiol Infect, 20, 45, 10.1111/1469-0691.12461 Scott, 2007, The preventable burden of pneumococcal disease in the developing world, Vaccine, 25, 2398, 10.1016/j.vaccine.2006.09.008 Ludwig, 2012, The remaining challenges of pneumococcal disease in adults, Eur Respir Rev, 21, 57, 10.1183/09059180.00008911 Said, 2013, Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques, PLoS One, 8, e60273, 10.1371/journal.pone.0060273 Chalmers, 2016, A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults, BMC Pulm Med, 16, 77, 10.1186/s12890-016-0242-0 Torres, 2013, Risk factors for community-acquired pneumonia in adults in Europe: a literature review, Thorax, 68, 1057, 10.1136/thoraxjnl-2013-204282 McCullers, 2014, The co-pathogenesis of influenza viruses with bacteria in the lung, Nat Rev Microbiol, 12, 252, 10.1038/nrmicro3231 Torres, 2015, Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease, Thorax, 70, 984, 10.1136/thoraxjnl-2015-206780 Curcio, 2015, Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence, Int J Infect Dis, 37, 30, 10.1016/j.ijid.2015.05.003 Feldman, 2016, Epidemiology, virulence factors and management of the pneumococcus, F1000Res, 5, 2320, 10.12688/f1000research.9283.1 Ram, 2010, Infections of people with complement deficiencies and patients who have undergone splenectomy, Clin Microbiol Rev, 23, 740, 10.1128/CMR.00048-09 Chidiac, 2012, Pneumococcal infections and adult with risk factors, Med Mal Infect, 42, 517, 10.1016/j.medmal.2012.04.003 Sinwar, 2014, Overwhelming post splenectomy infection syndrome – review study, Int J Surg, 12, 1314, 10.1016/j.ijsu.2014.11.005 Theilacker, 2016, Overwhelming postsplenectomy infection: a prospective multicenter cohort study, Clin Infect Dis, 62, 871, 10.1093/cid/civ1195 Martinot, 2014, Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections, Int J Infect Dis, 79, 79, 10.1016/j.ijid.2013.10.020 Picard, 2011, Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency, Clin Microbiol Rev, 24, 490, 10.1128/CMR.00001-11 Von Bernuth, 2012, Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans, Eur J Immunol, 42, 3126, 10.1002/eji.201242683 Calbo, 2011, Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections, Curr Opin Infect Dis, 24, 241, 10.1097/QCO.0b013e3283463e45 Vernatter, 2013, Current concepts in host-microbe interaction leading to pneumococcal pneumonia, Curr Opin Infect Dis, 26, 277, 10.1097/QCO.0b013e3283608419 Henriques-Normark, 2013, The pneumococcus: epidemiology, microbiology, and pathogenesis, Cold Spring Harb Perspect Med, 3, 010215, 10.1101/cshperspect.a010215 Donkor, 2014, Insights into pneumococcal pathogenesis and antibiotic resistance, Adv Microbiol, 4, 627, 10.4236/aim.2014.410069 Wootton, 2014, The pathophysiology of pneumococcal pneumonia, vol. 63, 42 Song, 2013, Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance, J Korean Med Sci, 28, 4, 10.3346/jkms.2013.28.1.4 Ritchie, 2012, What is different about serotype 1 pneumococci?, Future Microbiol, 7, 33, 10.2217/fmb.11.146 Luján, 2006, Optimal therapy for severe pneumococcal community-acquired pneumonia, Intensive Care Med, 32, 971, 10.1007/s00134-006-0182-x Grabenstein, 2014, Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults, Vaccine, 32, 2399, 10.1016/j.vaccine.2014.02.096 Harboe, 2009, Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study, PLoS Med, 6, e1000081, 10.1371/journal.pmed.1000081 Jansen, 2009, Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome, Clin Infect Dis, 49, e23, 10.1086/600045 Weinberger, 2010, Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis, Clin Infect Dis, 51, 692, 10.1086/655828 Garcia-Vidal, 2010, Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes, Thorax, 65, 77, 10.1136/thx.2009.123612 Ahl, 2013, High incidence of septic shock caused by Streptococcus pneumoniae serotype 3 – a retrospective epidemiological study, BMC Infect Dis, 13, 492, 10.1186/1471-2334-13-492 Burgos, 2014, Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes, Eur Respir J, 43, 545, 10.1183/09031936.00050413 Fruchtman, 1983, Adult respiratory distress syndrome as a cause of death in pneumococcal pneumonia. Report of ten cases, Chest, 83, 598, 10.1378/chest.83.4.598 Witzenrath, 2006, Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia, Crit Care Med, 34, 1947, 10.1097/01.CCM.0000220496.48295.A9 Rubins, 1993, Toxicity of pneumolysin to pulmonary alveolar epithelial cells, Infect Immun, 61, 1352, 10.1128/IAI.61.4.1352-1358.1993 Witzenrath, 2007, Role of platelet-activating factor in pneumolysin-induced acute lung injury, Crit Care Med, 35, 1756, 10.1097/01.CCM.0000269212.84709.23 Musher, 2007, The association between pneumococcal pneumonia and acute cardiac events, Clin Infect Dis, 45, 158, 10.1086/518849 Brown, 2014, Steptococcus pnemoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function, PLoS Pathog, 10, e1004383, 10.1371/journal.ppat.1004383 Alhamdi, 2015, Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection, PLoS Pathog, 11, e1004836, 10.1371/journal.ppat.1004836 Brown, 2015, Cardiotoxicity during invasive pneumococcal disease, Am J Respir Crit Care Med, 191, 739, 10.1164/rccm.201411-1951PP Mandell, 2007, Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, Clin Infect Dis, 44, S27, 10.1086/511159 Woodhead, 2011, Guidelines for the management of adult lower respiratory tract infections – full version, Clin Microbiol Infect, 17, E1, 10.1111/j.1469-0691.2011.03672.x Lim, 2015, British Thoracic Society community-acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together, Thorax, 70, 698, 10.1136/thoraxjnl-2015-206881 Baddour, 2004, Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia, Am J Respir Crit Care Med, 170, 440, 10.1164/rccm.200311-1578OC Lodise, 2007, Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia, Antimicrob Agents Chemother, 51, 3977, 10.1128/AAC.00006-07 Sligl, 2014, Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis, Crit Care Med, 42, 420, 10.1097/CCM.0b013e3182a66b9b Gattarello, 2014, Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013), Chest, 146, 22, 10.1378/chest.13-1531 Gattarello, 2015, What is new in antibiotic therapy in community-acquired pneumonia? An evidence-based approach focusing on combined therapy, Curr Infect Dis Rep, 17, 501, 10.1007/s11908-015-0501-x Feldman, 2009, Therapy for pneumococcal bacteremia: monotherapy or combination therapy?, Curr Opin Infect Dis, 22, 137, 10.1097/QCO.0b013e3283232a30 Berjohn, 2008, Treatment and outcomes for patients with bacteremic pneumococcal pneumonia, Medicine, 87, 160, 10.1097/MD.0b013e318178923a Mongardon, 2012, Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study, Crit Care, 16, R155, 10.1186/cc11471 GBD 2013 Mortality and Causes of Death Collaborators, 2015, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 385, 117, 10.1016/S0140-6736(14)61682-2 Wunderink, 2012, Adjunctive therapy in community-acquired pneumonia, Semin Respir Crit Care Med, 33, 311, 10.1055/s-0032-1315643 Faverio, 2014, Non-antibiotic therapies for CAP, vol. 63, 219 Lucas, 2013, Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs, Toxins, 5, 1244, 10.3390/toxins5071244 Mitchell, 2014, The biology of pneumolysin, Subcell Biochem, 80, 145, 10.1007/978-94-017-8881-6_8 Geno, 2015, Pneumococcal capsules and their types: past, present, and future, Clin Microbiol Rev, 28, 871, 10.1128/CMR.00024-15 Kirkham, 2006, Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin, J Clin Microbiol, 44, 151, 10.1128/JCM.44.1.151-159.2006 Jefferies, 2007, Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks, J Infect Dis, 196, 936, 10.1086/520091 Price, 2009, Pneumolysin localizes to the cell wall of Streptococcus pneumonia, J Bacteriol, 191, 2163, 10.1128/JB.01489-08 Farrand, 2010, Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface, Proc Natl Acad Sci USA, 107, 4341, 10.1073/pnas.0911581107 Bokori-Brown, 2016, Red blood cell susceptibility to pneumolysin: correlation with membrane biochemical and physical properties, J Biol Chem, 291, 10210, 10.1074/jbc.M115.691899 Gilbert, 2016, Measuring kinetic drivers of pneumolysin pore structure, Eur Biophys J, 45, 365, 10.1007/s00249-015-1106-x Wolfmeier, 2015, Ca2+-dependent repair of pneumolysin pores: a new paradigm for host cellular defense against bacterial pore-forming toxins, Biochim Biophys Acta, 1853, 2045, 10.1016/j.bbamcr.2014.09.005 Wolfmeier, 2016, Active release of pneumolysin prepores and pores by mammalian cells undergoing a Streptococcus pneumoniae attack, Biochim Biophys Acta, 1860, 2498, 10.1016/j.bbagen.2016.07.022 Clark, 1986, Oxidative inactivation of pneumolysin by the myeloperoxidase system and stimulated human neutrophils, J Immunol, 136, 4617, 10.4049/jimmunol.136.12.4617 Ali, 2013, Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae, PLoS One, 8, e82583, 10.1371/journal.pone.0082583 Feldman, 2016, The role of Streptococcus pneumoniae in community-acquired pneumonia, Semin Respir Crit Care Med, 37, 806, 10.1055/s-0036-1592074 Zafar, 2017, Host-to-host transmission of Streptococcus pneumoniae is driven by its inflammatory toxin, pneumolysin, Cell Host Microbe, 21, 73, 10.1016/j.chom.2016.12.005 Nelson, 2007, Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance, Infect Immun, 75, 83, 10.1128/IAI.01475-06 Feldman, 1990, The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro, Microb Pathog, 9, 275, 10.1016/0882-4010(90)90016-J Hotomi, 2016, Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization, Folia Microbiol, 61, 375, 10.1007/s12223-016-0445-z Hermand, 2017, Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen, Hum Vaccin Immunother, 13, 220, 10.1080/21645515.2016.1234553 Zhang, 2009, Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice, J Clin Invest, 119, 1899 Bergmann, 2009, Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells, J Cell Sci, 122, 256, 10.1242/jcs.035600 Thornton, 2011, Multi-species bacterial biofilm and intracellular infection in otitis media, BMC Pediatr, 11, 94, 10.1186/1471-2431-11-94 Marks, 2012, Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo, Infect Immun, 80, 2744, 10.1128/IAI.00488-12 McCullers, 2006, Insights into the interaction between influenza virus and pneumococcus, Clin Microbiol Rev, 19, 571, 10.1128/CMR.00058-05 Jones, 2013, M2 macrophage polarisation is associated with alveolar formation during postnatal lung development, Respir Res, 14, 41, 10.1186/1465-9921-14-41 Yang, 2016, Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in vitro, Immunopharmacol Immunotoxicol, 10.1080/08923973.2016.1248845 González-Juarbe, 2015, Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia, PLoS Pathog, 11, e1005337, 10.1371/journal.ppat.1005337 Kitur, 2015, Toxin-induced necroptosis is a major mechanism of Staphylococcus aureus lung damage, PLoS Pathog, 11, e1004820, 10.1371/journal.ppat.1004820 Gilley, 2016, Infiltrated macrophages die of pneumolysin-mediated necroptosis following pneumococcal myocardial invasion, Infect Immun, 84, 1457, 10.1128/IAI.00007-16 Aberdein, 2013, Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing, Clin Exp Immunol, 174, 193, 10.1111/cei.12170 Bewley, 2014, Pneumolysin activates macrophage lysosomal membrane permeabilization and executes apoptosis by distinct mechanisms without membrane pore formation, MBio, 5, 10.1128/mBio.01710-14 Chen, 2014, Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death, Cell Res, 24, 105, 10.1038/cr.2013.171 Lemon, 2015, Degradation products of the extracellular pathogen Streptotoccus pneumoniae access the cytosol via its pore-forming toxin, MBio, 6, e02110, 10.1128/mBio.02110-14 Karmakar, 2015, Neutrophil IL-1β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux, J Immunol, 194, 1763, 10.4049/jimmunol.1401624 Hassane, 2017, Neutrophilic NLRP3 inflammasome-dependent IL-1β secretion regulates the γδT17 cell response in respiratory bacterial infections, Mucosal Immunol, 10.1038/mi.2016.113 García-Suárez Mdel, 2007, The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model, Respir Res, 8, 3, 10.1186/1465-9921-8-3 Ohkuni, 2012, Characterization of recombinant Streptococcus mitis-derived human platelet aggregation factor, APMIS, 120, 56, 10.1111/j.1600-0463.2011.02813.x Nel, 2016, Pneumolysin mediates platelet activation in vitro, Lung, 194, 589, 10.1007/s00408-016-9900-5 Nel, 2017, Pneumolysin mediates heterotypic aggregation of neutrophils and platelets in vitro, J Infect, 74, 599, 10.1016/j.jinf.2017.02.010 Bonten, 2015, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med, 372, 1114, 10.1056/NEJMoa1408544 Bruce, 2015, Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska, Vaccine, 33, 4813, 10.1016/j.vaccine.2015.07.080 Nair, 2016, Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children, BMC Infect Dis, 16, 390, 10.1186/s12879-016-1693-x Feldman, 2016, Community-acquired pneumonia: still a major burden of disease, Curr Opin Crit Care, 22, 477, 10.1097/MCC.0000000000000340 García-Suárez Mdel, 2004, Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin, Infect Immun, 72, 4534, 10.1128/IAI.72.8.4534-4540.2004 Cockeran, 2005, Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease, Arch Immunol Ther Exp, 53, 189 Li, 2015, β-Sitosterol interacts with pneumolysin to prevent Streptococcus pneumoniae infection, Sci Rep, 5, 17668, 10.1038/srep17668 Henry, 2015, Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice, Nat Biotechnol, 33, 81, 10.1038/nbt.3037 Zhao, 2016, Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers, Mol Pharmacol, 89, 376, 10.1124/mol.115.100610 Song, 2016, Apigenin protects mice from pneumococcal pneumonia by inhibiting the cytolytic activity of pneumolysin, Fitoterapia, 115, 31, 10.1016/j.fitote.2016.09.017 Zhao, 2017, Anticytotoxin effects of amentoflavone to pneumolysin, Biol Pharm Bull, 40, 61, 10.1248/bpb.b16-00598 Spoorenberg, 2014, Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis, BMC Infect Dis, 14, 335, 10.1186/1471-2334-14-335 Jain, 2015, Community-acquired pneumonia requiring hospitalization among U.S. adults, N Engl J Med, 373, 415, 10.1056/NEJMoa1500245 Martin-Loeches, 2010, Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia, Intensive Care Med, 36, 612, 10.1007/s00134-009-1730-y Bender, 2016, Improving outcomes in community-acquired pneumonia, Curr Opin Pulm Med, 22, 235, 10.1097/MCP.0000000000000257 Emmet O'Brien, 2015, Update on the combination effect of macrolide antibiotics in community-acquired pneumonia, Respir Investig, 53, 201, 10.1016/j.resinv.2015.05.003 Horita, 2016, Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis, Respirology, 21, 1193, 10.1111/resp.12835 Shorr, 2013, Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study, BMJ Open, 3, e002898, 10.1136/bmjopen-2013-002898 Anderson, 2010, Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system, Pharmaceuticals, 3, 1694, 10.3390/ph3051694 Steel, 2012, Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics, Mediators Inflamm, 2012, 584262, 10.1155/2012/584262 Lagrou, 2000, Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro, J Antimicrob Chemother, 46, 717, 10.1093/jac/46.5.717 Spreer, 2003, Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone, Antimicrob Agents Chemother, 47, 2649, 10.1128/AAC.47.8.2649-2654.2003 Anderson, 2007, Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae, J Antimicrob Chemother, 59, 224, 10.1093/jac/dkl479 Anderson, 2007, Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro, J Antimicrob Chemother, 60, 1155, 10.1093/jac/dkm338 Spreer, 2007, Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in vitro, Chemotherapy, 53, 327, 10.1159/000107691 Fukuda, 2006, Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae, Eur Respir J, 27, 1020, 10.1183/09031936.06.00116805 Yanagihara, 2009, Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection, Intern Med, 48, 527, 10.2169/internalmedicine.48.1482 Kohno, 2014, Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia, J Infect Chemother, 20, 199, 10.1016/j.jiac.2013.10.010 Zhanel, 2014, Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data, J Antimicrob Chemother, 69, 2835, 10.1093/jac/dku207 Wolter, 2008, Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation, Antimicrob Agents Chemother, 52, 435, 10.1128/AAC.01074-07 Cockeran, 2012, Effects of clarithromycin at sub-minimum inhibitory concentrations on early ermB gene expression, metabolic activity and growth of an erm(B)-expressing macrolide-resistant strain of Streptococcus pneumoniae, Open J Respir Dis, 2, 1, 10.4236/ojrd.2012.21001 Zuckerman, 2004, Macrolides and ketolides: azithromycin, clarithromycin, telithromycin, Infect Dis Clin N Am, 18, 621, 10.1016/j.idc.2004.04.010 Weisblum, 1995, Insights into erythromycin action from studies of its activity as inducer of resistance, Antimicrob Agents Chemother, 39, 797, 10.1128/AAC.39.4.797 Wozniak, 2004, Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa, Chest, 125, 10.1378/chest.125.2_suppl.62S Cilloniz, 2015, The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia, Am J Respir Crit Care Med, 191, 1265, 10.1164/rccm.201502-0212OC Niederman, 2015, Macrolide-resistant pneumococcus in community-acquired pneumonia. Is there still a role for macrolide therapy?, Am J Respir Crit Care Med, 191, 1216, 10.1164/rccm.201504-0701ED Lin, 2003, Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro, Antimicrob Agents Chemother, 47, 1151, 10.1128/AAC.47.3.1151-1153.2003 Yoshioka, 2016, Efficacy of β-lactam-plus-macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia, Antimicrob Agents Chemother, 60, 6146, 10.1128/AAC.01024-16 Van Bambeke, 2016, The role of solithromycin in the management of bacterial community-acquired pneumonia, Expert Rev Anti Infect Ther, 14, 311, 10.1586/14787210.2016.1138857 Farrell, 2015, Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012, Antimicrob Agents Chemother, 59, 2432, 10.1128/AAC.04568-14 Viasus, 2017, Solithromycin for the treatment of community-acquired bacterial pneumonia, Expert Rev Respir Med, 11, 5, 10.1080/17476348.2017.1249852 Yamamoto, 2016, Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3, Pharmacol Res, 111, 804, 10.1016/j.phrs.2016.07.033 Harada, 2016, Premedication with clarithromycin is effective against secondary bacterial pneumonia during influenza virus infection in a pulmonary emphysema mouse model, J Pharmacol Exp Ther, 358, 457, 10.1124/jpet.116.233932 Sun, 2008, Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection, Nat Med, 14, 558, 10.1038/nm1765 Trinchieri, 2010, Type I interferon: friend or foe?, J Exp Med, 207, 2053, 10.1084/jem.20101664 Lorenzo, 2015, Lung inflammatory pattern and antibiotic treatment in pneumonia, Respir Res, 16, 15, 10.1186/s12931-015-0165-y Statt, 2015, Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells, Am J Respir Cell Mol Biol, 53, 689, 10.1165/rcmb.2014-0391OC Rosch, 2010, Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease, J Clin Invest, 120, 627, 10.1172/JCI39843 Feldman, 2015, Community-acquired pneumonia. Pathogenesis of acute cardiac events and potential adjunctive therapies, Chest, 148, 523, 10.1378/chest.15-0484 Viasus, 2015, The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial, BMJ Open, 5, e006251, 10.1136/bmjopen-2014-006251 Havers, 2016, Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia, Clin Infect Dis, 62, 1471, 10.1093/cid/ciw174 Wootton, 2016, Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins, Thorax, 71, 1052, 10.1136/thoraxjnl-2016-208505 Patel, 2016, Simvastatin improves neutrophil migration in elderly patients with septic pneumonia and reduces 6-month mortality and re-admissions: results of the SNOOPI Trial, Thorax, 71, A11, 10.1136/thoraxjnl-2016-209333.22 Grudzinska, 2016, Concurrent statin and macrolide use during pneumonia treatment improves survival to hospital discharge and beyond, Thorax, 71, A231, 10.1136/thoraxjnl-2016-209333.408 Tintinger, 2013, Pharmacological approaches to regulate neutrophil activity, Semin Immunopathol, 335, 395, 10.1007/s00281-013-0366-8 Barnes, 2011, Glucocorticosteroids: current and future directions, Br J Pharmacol, 163, 29, 10.1111/j.1476-5381.2010.01199.x Hua, 2016, Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex, Proc Natl Acad Sci USA, 113, E635, 10.1073/pnas.1522826113 Wagner, 1956, The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin, Bull Johns Hopkins Hosp, 98, 197 du Cheyron, 2003, Corticosteroids as adjunctive treatment in Austrian's syndrome (pneumococcal endocarditis, meningitis, and pneumonia): report of two cases and review of the literature, J Clin Pathol, 56, 879, 10.1136/jcp.56.11.879 Lavi, 2015, Systemic steroid treatment for severe expanding pneumococcal pneumonia, Case Rep Pediatr, 2015, 186302 Damjanovic, 2013, Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses, Am J Pathol, 183, 868, 10.1016/j.ajpath.2013.05.016 Ghoneim, 2014, Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice, J Infect Dis, 209, 1459, 10.1093/infdis/jit653 Siemieniuk, 2015, Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis, Ann Intern Med, 163, 519, 10.7326/M15-0715 Tagami, 2015, Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients, Eur Respir J, 45, 463, 10.1183/09031936.00081514 Feldman, 2016, Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials, J Thorac Dis, 8, E162, 10.21037/jtd.2016.02.43 Wirz, 2016, Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia, Eur Respir J, 48, 1150, 10.1183/13993003.00474-2016 Blum, 2015, Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial, Lancet, 385, 1511, 10.1016/S0140-6736(14)62447-8 Snijders, 2010, Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial, Am J Respir Crit Care Med, 181, 975, 10.1164/rccm.200905-0808OC Zhang, 2016, Effects of suilysin on Streptococcus suis-induced platelet aggregation, Front Cell Infect Microbiol, 6, 128, 10.3389/fcimb.2016.00128 Zhang, 2016, Suilysin-induced platelet-neutrophil complexes formation is triggered by pore formation-dependent calcium influx, Sci Rep, 6, 36787, 10.1038/srep36787 De Stoppelaar, 2014, The role of platelets in sepsis, Thromb Haemost, 112, 666, 10.1160/TH14-02-0126 Claushuis, 2016, Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients, Blood, 127, 3062, 10.1182/blood-2015-11-680744 Cangemi, 2014, Platelet activation is associated with myocardial infarction in patients with pneumonia, J Am Coll Cardiol, 64, 1917, 10.1016/j.jacc.2014.07.985 Cangemi, 2016, Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia, J Infect, 73, 107, 10.1016/j.jinf.2016.05.013 Winning, 2009, Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms, Platelets, 20, 50, 10.1080/09537100802503368 Erlich, 2011, Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study, Chest, 139, 289, 10.1378/chest.10-0891 O'Neal, 2011, Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome, Crit Care Med, 39, 1343, 10.1097/CCM.0b013e3182120992 Harr, 2013, Anti-platelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients, Crit Care Med, 41, 399, 10.1097/CCM.0b013e31826ab38b Falcone, 2015, Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin, J Am Heart Assoc, 4, e001595, 10.1161/JAHA.114.001595 Panka, 2016, Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies, Shock, 47, 13, 10.1097/SHK.0000000000000745 Kor, 2011, Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients, Crit Care Med, 39, 2393, 10.1097/CCM.0b013e318225757f Kor, 2016, Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial, JAMA, 315, 2406, 10.1001/jama.2016.6330 Voiriot, 2011, Nonsteroidal anti-inflammatory drugs may affect the presentation and course of community-acquired pneumonia, Chest, 139, 387, 10.1378/chest.09-3102 Gibelin, 2013, Lung abscess complicating pneumococcal pneumonia: a causal role of non-steroidal anti-inflammatory drugs?, BMJ Case Rep, 200544 Messika, 2014, Risks of nonsteroidal anti-inflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients, J Crit Care, 29, 733, 10.1016/j.jcrc.2014.05.021 Esposito, 1984, Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia, Am Rev Respir Dis, 130, 857 Stables, 2010, Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and –resistant bacteria, Blood, 116, 2950, 10.1182/blood-2010-05-284844 Lee, 2014, Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome, BMC Infect Dis, 14, 47, 10.1186/1471-2334-14-47 Shigematsu, 2016, Leukotriene B4 receptor type 2 protects against pneumolysin-dependent acute lung injury, Sci Rep, 6, 34560, 10.1038/srep34560 Pan, 2016, PAR-1 antagonists: an emerging antiplatelet drug class, 148 José, 2015, Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection, J Immunol, 194, 6024, 10.4049/jimmunol.1500124